Lurbinectedin Combo Induces Clinical Activity in Chemo-Sensitive SCLC

Article

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Martin David Forster, MD, PhD

Lurbinectedin (Zepsyre; PM1183) plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer (SCLC), especially when excluding refractory patients.

In particular, patients with chemotherapy-free intervals (CTFIs) of 90 days or more induced a 53% overall response rate (ORR) and PFS of 5.7 months, according to findings that were presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.1

Lurbinectedin is an investigational agent that received FDA orphan drug designation to treat patients with SCLC in August 2018. The agent inhibits RNA polymerase II, and by blocking trans-activated transcription, it induces apoptosis.2

“In transcriptionally addicted tumors, like SCLC, [lurbinectedin] cause a detachment of transcription factors from their promoters inhibiting its transactivity,” Martin Forster, MD, medical oncologist, University College London Hospitals, and colleagues wrote.

In a multicenter, phase Ib, 3+3 dose-escalation study, investigators administered 3-mg to 5-mg full-dose lurbinectedin plus 50 mg/m2 doxorubicin, followed by dose expansion at radiotherapy dose to patients with select advanced diseases, including SCLC.

Findings of cohort A of this trial demonstrated clinical activity in the second-line setting among patients with SCLC with an objective response rate (ORR) of 67%. The partial response (PR) rate was 57% and the complete response (CR) rate was 10% (95% CI, 43%-85%). This activity was particularly significant in sensitive patients (chemotherapy-free interval [CTFI] >90 days), who induced an ORR of 100% (n = 11; PR, 82%; CR, 18%; 95% CI, 71.5%-100%).

The researchers conducted an expansion cohort with a reduced dose to improve efficacy and safety in the endometrial cancer and SCLC subgroups, which were also presented at this meeting (cohort B).

The trial included 28 patients aged <75 years with an ECOG performance score of 0 or 1 and with no more than 1 prior chemotherapy line and stable brain metastases who were treated with 2 mg/m2 lurbinectedin plus 40 mg/m2 doxorubicin on day 1 of each cycle every 3 weeks. Patients continued on 4 mg/m2 lurbinectedin after the doxorubicin cumulative dose of 450 mg/m2 was reached.

The majority of patients were male (75%), with a median age of 64 years (49-77). In addition, 68% had an ECOG performance score of 1, 4% had central nervous system (CNS) involvement, and 75% has bulky disease (>50 mm).

Median CTFI was 3.4 months (0-15.9), of which 36% were resistant (CTFI <90 days), and 64% were sensitive (CTFI >90 days). Median time to progression to the first-line platinum-based combination was 6.8 months (1.4-18.9).

The overall ORR was 37%—11% in resistant patients (n = 9) and 50% in the sensitive cohort (n = 18). When patients with CTFI <30 days were excluded, overall ORR was 48%, 33% in resistant patients (n = 3) and 50% in sensitive patients (n = 18).

Overall median progression-free survival (PFS) was 3.4 months (95% CI, 2-6), 1.5 months in the resistant cohort (95% CI, 1-5), and 5.7 months in the sensitive cohort (95% CI, 3-8). Overall 6-month PFS was 37% (95% CI, 19-55), 11.1% in resistant patients (95% CI, 0%-32%) and 50% in sensitive patients (95% CI, 27%-73%).

When the investigators excluded patients with CTFI <30 days, median PFS in the overall population improved to 5.3 months (95% CI, 2-7), and to 1.9 months (95% CI, 1-6) in the resistant cohort. Similarly, 6-month PFS improved to 47.6% in the entire cohort, and to 33.3% in resistant patients (95% CI, 0%-87%).

Overall median OS was 7.9 months (95% CI, 5-12), 4.9 months in resistant patients (95% CI, 2-7), and 11.5 months in sensitive patients (95% CI, 6-17). Moreover, overall 6- and 12-month OS rates were 59.2% (95% CI, 40%-79%) and 22.4% (95% CI, 4%-41%), respectively, 33% (95% CI, 3%-64%) and 0% (95% CI, 0%-0%) in resistant patients, and 75.4% (95% CI, 54%-97%) and 33.9% (96% CI, 8%-60%) in sensitive patients.

Excluding patients with CTFI <30 days, overall OS was 10.2 months (95% CI, 6-12), 6.7 months in resistant patients (95% CI, 5-8) and 11.5 months in sensitive patients (95% CI, 6-17). Overall 6- and 12-month OS was 73.6% (95% CI, 54%-95%) and 27.8% (95% CI, 5%-50%), respectively, 66.7% (95% CI, 13%-100%) and 0% (95 CI, 0%-0%) in the resistant group, and 75.4% (95% CI, 54%-96%) and 33.9% (95% CI, 8%-60%) in the sensitive group.

“OS shows a remarkable improvement in this second-line setting, especially when excluding refractory patients,” the researchers wrote.

The most common grade 4 adverse events (AEs) included neutropenia (68%), thrombocytopenia (11%), febrile neutropenia (7%), and aspartate aminotransferase (4%).

“Main hematological toxicity was myelosuppression, (which was) well-managed with (granulocyte colony-stimulating factor) and dose reductions,” the researchers added.

A phase III clinical trial (ATLANTIS, NCT02566993) is currently ongoing evaluating this combination in patients with relapsed SCLC.

“(The) lurbinectedin/doxorubicin combination showed remarkable activity (in the) second-line setting in SCLC, especially in sensitive patients,” the researchers wrote. “Activity is higher than reported for CAV (cyclophosphamide, doxorubicin [Adriamycin], and vincristine) or topotecan.”

References

  1. Forster M, Moreno V, Calvo E, et al. Overall survival with lurbinectedin plus doxorubicin in relapsed SCLC: results from an expansion cohort of a phase Ib trial. In: Proceedings from the IASLC 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada. Abstract P1.12-20.
  2. Perez JMT, Leary A, Besse B, et al. Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study. J Clin Oncol. 2018;36(suppl; abstr 8570)
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.